Skip to main content

Table 4 Clinical UPDRS-III, S and E scales and H and Y stages scores of PD MC and NC patients undergoing STN-DBS (mean ± SD)

From: Greater improvement in LRRK2 G2019S patients undergoing Subthalamic Nucleus Deep Brain Stimulation compared to non-mutation carriers

Medication stimulation

UPDRS-III

S and E scale

H and Y scale

situations

MC

NC

MC

NC

MC

NC

Off–Off

55.8 ± 16.4

51.7 ± 14.4

0.43 ± 0.18

0.52 ± 0.14

3.50 ± 0.86

3.54 ± 0.65

On–Off

25.0 ± 13.2

30.6 ± 16.7

0.70 ± 0.13

0.69 ± 0.16

2.36 ± 0.66

2.87 ± 0.90

Off–On

27.3 ± 20.6

38.5 ± 16.6

0.60 ± 0.21

0.60 ± 0.26

2.36 ± 0.69

2.16 ± 0.91

On–On

19.7 ± 18.8

18.8 ± 12.5

0.85 ± 0.16

0.89 ± 0.10

2.13 ± 0.71

1.91 ± .99

p

0.00005

0.0003

0.00001

0.00106

0.00002

0.00091

  1. Unified parkinson’s disease rating scale III (UPDRS-III); Hoehn and Yahr scale (H and Y scale); Schwab and England’s activities of daily living scale (S and E scale)
  2. MC mutation carriers, NC non mutation carriers